PDL BioPharma, Inc. Average Common Equity

Average Common Equity of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Average Common Equity growth rates and interactive chart.


Highlights and Quick Summary

  • Average Common Equity for the quarter ending June 29, 2020 was $543 Million (a -12.95% decrease compared to previous quarter)
  • Year-over-year quarterly Average Common Equity decreased by -21.16%
  • Annual Average Common Equity for 2019 was $662 Million (a -16.03% decrease from previous year)
  • Annual Average Common Equity for 2018 was $788 Million (a -1.6% decrease from previous year)
  • Annual Average Common Equity for 2017 was $801 Million (a 10.33% increase from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Average Common Equity of PDL BioPharma, Inc.

Most recent Average Common Equityof PDLI including historical data for past 10 years.

Interactive Chart of Average Common Equity of PDL BioPharma, Inc.

PDL BioPharma, Inc. Average Common Equity for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $542.71 $623.45
2019 $661.53 $688.41 $689.03 $768.45 $661.53
2018 $787.83 $781.18 $765.71 $803.02 $787.83
2017 $800.66 $788.42 $778.73 $752.73 $800.66
2016 $725.69 $674.91 $632.93 $597.24 $725.69
2015 $578.19 $498.98 $411.94 $327.08 $578.19
2014 $286.96 $227.45 $147.7 $54.27 $286.96
2013 $22.68 $-31.3 $-81.19 $-168.73 $22.68
2012 $-136.2 $-179.36 $-227.31 $-307.49 $-136.2
2011 $-264.23 $-273.89 $-364.18 $-436.13 $-264.23
2010 $-370.07 $-273.47 $-370.92 $-370.07

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.